OSR Health 遭 Nasdaq Hearing Panel 决定摘牌，证券仍在场外市场报价

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2026

(Exact Name of Registrant as Specified in Charter)

Registrant’s telephone number, including area code (425) 635-7700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, trading in the common stock and warrants of OSR Health, Inc. (the “Company”) on The Nasdaq Stock Market LLC (“Nasdaq”) was suspended effective at the open of trading on August 26, 2026, due to the Company’s non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), and the Company requested a hearing before the Nasdaq Hearings Panel (the “Panel”).

On October 23, 2026, the Company received a written decision from the Panel denying the Company’s request for continued listing and determining to delist the Company’s securities from Nasdaq. The Company’s securities continue to be quoted on the over-the-counter market under the symbols “OSRH” and “OSRHW.” The Company is evaluating its options.

Item 7.01. Regulation FD Disclosure.

On October 28, 2026, the Company issued a press release providing an update to shareholders following the Panel’s decision. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 28, 2026